Take Ltd (TAKE)

Healthcare · Healthcare · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹14.7 ↑ 39.34% (1Y)

🎯 Key Takeaways

TAKE Limited is transitioning from a period of financial distress to operational stabilization, marked by a return to profitability and strategic repositioning in the high-growth longevity and preventive healthcare space. The company reversed a prior-year net loss to report a consolidated net profit of ₹1.
Revenue declined 44% QoQ to ₹30 in Q1FY27.
⚠️ Revenue volatility remains high, with inconsistent top-line performance across quarters, raising questions about business model scalability.

Market Cap

₹217

P/E Ratio

17.1

P/B Ratio

10.58

ROE

62.5%

ROCE

30.4%

Debt/Equity

0.00

Promoter

0.0%

✨ Ask AI About TAKE 📊 Interactive Charts

📖 The Story

TAKE Limited is transitioning from a period of financial distress to operational stabilization, marked by a return to profitability and strategic repositioning in the high-growth longevity and preventive healthcare space. The company reversed a prior-year net loss to report a consolidated net profit of ₹1.06 Cr in Q1 FY27, supported by minimal finance costs and a lean balance sheet. Management is actively pivoting toward science-backed nutraceuticals and digital longevity solutions, targeting India's expanding preventive healthcare market.

📰 What's Happening

In Q1 FY27, TAKE Limited returned to profitability with consolidated revenue of ₹30.37 Cr and net profit of ₹1.06 Cr, reversing a ₹6.97 Cr loss in the previous fiscal year. Finance costs dropped 99.6% to ₹0.07 Lakhs, reflecting a significantly de-risked balance sheet. The board endorsed a strategic shift into biohacking, nutraceuticals, and digital longevity platforms, emphasizing high-margin, recurring revenue models. Shareholders are set to vote on appointing Sunil Patra as Managing Director, a move seen as critical for leadership continuity during this turnaround phase.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	0	0	54	30
Operating Profit	-0	-0	-1	-0
OPM %	—	—	-1.5%	-0.9%
Net Profit	6	1	4	1
EPS	₹0.43	₹0.07	₹0.29	₹0.07

The company's financial trajectory shows a sharp improvement in profitability, transitioning from consecutive quarters of near-zero revenue and negative operational performance to modest but positive net earnings. While revenue remains volatile (₹54 Cr in Mar 2026, ₹30 Cr in Jun 2026), profitability has stabilized with net profit of ₹1 Cr in the latest quarter. This turnaround is attributed to cost rationalization and the absence of prior-year divestment gains, as noted in the FY26 filing. The business appears to be bottoming out, with early signs of operational stabilization ahead of a strategic pivot.

🔮 Management Outlook & What's Next

Management has explicitly outlined plans to enter India's longevity and anti-aging market through science-backed nutraceuticals and digital preventive healthcare solutions, targeting high-margin, recurring revenue streams. This strategic shift is framed as a growth catalyst aligned with rising consumer demand for wellness and preventive care. The company emphasizes operational efficiency and capital discipline, with no major capital expenditures disclosed. Management maintains confidence in sustainable profitability and long-term value creation through this new vertical.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	15	15	15	15
Reserves	-29	6	11	16
Borrowings	8	0	0	0
Total Liabilities	87	36	35	36
Fixed Assets	0	0	0	0
Investments	0	0	0	0
Total Assets	87	36	35	36

The balance sheet reflects a pristine capital structure with zero net debt and steadily rising equity, which has grown from ₹3,100.14 Lakhs in FY26 to ₹3,100.14 Lakhs (equity and reserves combined at ₹31 Cr as of Mar 2026). With no borrowings and minimal finance costs, the company is in a strong position to fund growth internally. The focus appears to be on preserving capital while scaling new initiatives, suggesting a conservative and de-risked approach to expansion.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	-16
Investing	+22
Financing	-3
Net Cash Flow	+3

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	5.2%	0.0%	0.0%	0.0%
FII	0.0%	0.6%	0.3%	0.2%
DII	0.0%	0.0%	0.0%	0.0%
Public	40.4%	38.8%	31.6%	29.6%
# Shareholders	74,410	70,324	64,699	63,213

Institutional holding has declined slightly in recent quarters, with FII shareholding dropping from 0.56% in Q3FY26 to 0.21% in Q1FY27, while public ownership has also trended downward from 40.4% to 29.63%. However, the number of public shareholders has increased, indicating broader retail interest. Promoter holding remains at 0%, suggesting no insider accumulation. The reduction in institutional interest may reflect lingering concerns over governance or transparency, despite improving financials.

⚖️ Peer Comparison — Healthcare

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
APOLLOHOSP	1.26 L Cr	60.3	22.1%	22.9%	0.60
MANIPALHOS	98,259	—	—	—	1.25
MAXHEALTH	98,006	67.2	14.4%	13.6%	0.27
FORTIS	68,769	65.6	13.3%	10.8%	0.29
ASTERDM	66,090	122.7	17.2%	11.9%	0.21
NH	39,605	48.2	13.7%	18.0%	1.07
MEDANTA	39,163	70.4	21.9%	16.3%	0.10
LALPATHLAB	31,910	45.9	29.6%	21.8%	0.00
KIMS	31,878	148.8	9.7%	8.7%	1.44
POLYMED	17,790	56.5	15.1%	11.3%	0.06

🔗 Peer Stock Analyses

APOLLOHOSP MANIPALHOS MAXHEALTH FORTIS ASTERDM

⚠️ Risk Factors

1. Revenue volatility remains high, with inconsistent top-line performance across quarters, raising questions about business model scalability. 2. The qualified auditor's opinion over unresolved tax disputes totaling ₹1,247.60 Lakhs introduces potential contingent liabilities, despite management's assertion of full recoverability. 3. The strategic pivot to longevity and nutraceuticals lacks proven revenue traction and may require significant investment to gain market share. 4. Low and declining institutional ownership could limit liquidity and investor confidence during the turnaround phase.

📋 Recent Filings

🧠 Analyst's Read

TAKE Limited is in the early stages of a strategic transformation, with financial recovery now underway but still fragile. The company's shift into high-growth wellness and longevity markets offers a potential catalyst, but execution risks and governance transparency remain key concerns. Investors should monitor the outcome of the shareholder vote on management appointment and the pace of revenue growth in the new verticals as leading indicators of sustainable turnaround momentum.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on TAKE

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TAKE files new disclosures

Track TAKE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TAKE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd